Abbott Laboratories (NYSE:ABT) Declares Quarterly Dividend of $0.63

Abbott Laboratories (NYSE:ABT) declared a quarterly dividend on Friday, December 12th. Stockholders of record on Thursday, January 15th will be given a dividend of 0.63 per share by the healthcare product maker on Friday, February 13th. This represents a c) dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. This is a 6.8% increase from Abbott Laboratories’s previous quarterly dividend of $0.59.

Abbott Laboratories has increased its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 54 years. Abbott Laboratories has a dividend payout ratio of 44.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Abbott Laboratories to earn $5.73 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 44.0%.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $124.63 on Tuesday. The firm has a market capitalization of $216.72 billion, a PE ratio of 15.62, a PEG ratio of 2.09 and a beta of 0.72. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The firm’s fifty day simple moving average is $126.15 and its 200 day simple moving average is $129.24.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. The company had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period last year, the business posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Institutional Trading of Abbott Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABT. IMG Wealth Management Inc. raised its holdings in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 167 shares during the period. Cloud Capital Management LLC bought a new position in Abbott Laboratories during the 3rd quarter worth about $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories during the 3rd quarter worth about $31,000. Anfield Capital Management LLC lifted its holdings in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares in the last quarter. Finally, Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories during the second quarter worth about $32,000. Institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.